Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onalespib and AT7519 in Advanced Solid Tumors
NCT02503709Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2016
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of onalespib and AT-7519 in solid tumor (advanced stage), sponsored by National Cancer Institute. Primary endpoints: Incidence of adverse events, Tolerability of onalespib and CDKI AT7519 and 1 more. Started Sep 2016; status: completed.
02
Drugs
onalespibAT-7519
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02503709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02503709.